Oramed Pharmaceuticals, Inc.
Climate Impact & Sustainability Data (2012-08 to 2013-08)
Reporting Period: 2012-08 to 2013-08
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- History of unprofitable operations and uncertainty about future funding.
- Unpredictability of FDA approval process.
- Risks associated with partnerships and licensing deals.
- Lack of diversification beyond diabetes therapeutics.
- Competition from established pharmaceutical companies.
- Geopolitical risks associated with operations in Israel.
- Intellectual property risks.
- Reimbursement risks due to healthcare reform.
- Limited cash balance to sustain operations.
Mitigation Strategies
- Successfully raised $4.6 million through a registered direct public offering.
- Focus on risk-mitigated drug development (insulin and GLP-1 agonists).
- Strategic partnerships or acquisition as a commercialization strategy.